4553 — Towa Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual cashflow statement for Towa Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	22,246	4,605	24,459	26,330	13,165
Depreciation
Amortisation
Non-Cash Items	-2,350	1,914	-5,433	-795	11,043
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-8,721	-23,383	-28,701	-22,021	-16,616
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	22,129	2,545	8,213	23,613	30,429
Capital Expenditures	-13,576	-30,469	-39,325	-31,223	-24,128
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-46,153	185	-1,069	-64	-1,532
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-59,729	-30,284	-40,394	-31,287	-25,660
Financing Cash Flow Items	-26	-156	21	23	38
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	46,540	17,481	35,407	21,567	-6,828
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	9,915	-8,573	5,393	15,809	-649